

**AMENDMENTS TO THE DRAWINGS**

Please delete the drawing submitted with the original application and insert the attached substitute drawing page.

Submitted herewith please find one (1) replacement drawing in compliance with 37 C.F.R. § 1.84. The Examiner is respectfully requested to acknowledge receipt of this replacement drawing.

The submitted drawing is intended to replace the drawing previously submitted.

Attachment: Replacement Sheet: One (1)

**REMARKS**

Claims 1-2 are all the claims pending in the application. As will be discussed below, the specification has been amended at pages 3 and 9-10 to provide a brief description of the drawing and to reference the drawing, and at pages 14 and 15 to more clearly explain the column headings in Tables 1 and 2. The other amendments have been made to resolve issues raised by the Examiner. No new matter has been added. Accordingly, entry of the present Amendment is requested.

**Preliminary Matters**

Applicant thanks the Examiner for acknowledging the Information Disclosure Statement, filed December 23, 2005, and Applicant's Declaration, filed February 9, 2007.

**Objection to the Drawing**

On page 2 of the Office Action, the drawing (flowchart labeled "Scheme" on page 11 of the specification) has been objected to because the drawing is currently contained within the specification. Further, the Examiner suggests a more descriptive title for the drawing.

In response, the corrected drawing (Replacement Sheet 1 of 1) is provided herewith on a separate sheet of paper. Further, the Examiner's suggested title has been incorporated into the replacement drawing.

Accordingly, withdrawal of this objection is requested.

**Objection to the Specification**

(A) On page 3 of the Office Action, the specification has been objected to because a reference to and a brief description of the drawing is required.

In response, the specification has been amended at pages 3 and 9-10 to include a brief description of the drawing and a reference to the drawing, respectively.

Accordingly, withdrawal of this objection is requested.

(B) On page 3 of the Office Action, the specification was objected to because the “Sum of Tumors” column headings in Tables 1 and 2 (pages 14 and 15, respectively) are not explained.

In response, the specification has been amended at the column headings of Tables 1 and 2 to recite “Adenoma or Carcinoma.” Support for the amendment may be found in the specification, e.g., at page 15, lines 1-2, and 9-10.

Accordingly, withdrawal of this objection is requested.

**Claim Rejections - 35 U.S.C. § 112**

On page 3 of the Office Action, Claims 1 and 2 are rejected under 35 U.S.C. § 112, first paragraph, because the specification allegedly does not enable a person skilled in the art to use the invention commensurate in scope with the claims.

The Examiner discusses in detail the eight factors set forth in the *In re Wands* case concerning whether or not a disclosure would require undue experimentation, and indicates that the present specification fails to provide guidance that would allow the skilled artisan sufficient background to practice the claimed invention without resorting to undue experimentation.

Applicant traverses the rejection for the following reasons.

Applicants initially submit that the key issue is whether the specification enables one skilled in the art to make and use the overall scope of the claimed invention without undue experimentation. While the Examiner indicates that the specification does not provide guidance as to a particular dosage, Applicants respectfully submit that the specification does not need to provide such guidance. Rather, the specification simply needs to enable one skilled in the art to treat tumorigenesis without undue experimentation.

In this regard, Applicant respectfully submit that the specification does provide guidance to one skilled in the art by disclosing, e.g., that the dosage of Compound I will depend on factors such as age and/or weight of a subject, a type of carcinogens considered to be a cause of tumorigenesis, or an amount and a period of time of exposure to such a carcinogen. *See*, page 6, lines 22-25 in the specification.


Also, Applicant respectfully submits that the specification discloses that while oral administration is contemplated, delivery may be by parenteral administration, and local administration. *See*, page 6, lines 11-14 in the specification.

Accordingly, Applicant respectfully submits that the claimed invention is enabled in view of the *In re Wands* factors and that sufficient guidance is set forth in the specification such that one would not need to carry out undue experimentation to practice the overall scope of the invention. Accordingly, Applicant requests that the Examiner reconsider her position in view of the details set forth in the specification.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

  
John T. Callahan  
Registration No. 32,607

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 27, 2008